康泰生物(300601.SZ)：三价流感病毒裂解疫苗(MDCK细胞)获得药物临床试验批准通知书

Core Viewpoint - Kangtai Biological (300601.SZ) has received approval from the National Medical Products Administration for clinical trials of its trivalent influenza virus split vaccine (MDCK cells) [1] Company Summary - The trivalent influenza virus split vaccine is developed in collaboration with Lanzhou Bailing Biotechnology Co., Ltd. [1] - The vaccine is intended for individuals aged 3 years and older, aiming to stimulate the immune response against influenza viruses [1] Industry Summary - The approval aligns with the requirements set forth by the Drug Administration Law and Vaccine Administration Law of the People's Republic of China [1] - The vaccine is designed to prevent influenza caused by vaccine-related virus strains, addressing public health needs [1]